On Saturday, the Subject Expert Committee (SEC) on Covid-19 of the Central Pharmaceutical Standards Authority (CDSCO) filed for an Emergency Use Authorization (EUA) for a Hyderabad-based pharmaceutical company after submitting additional data, facts and analyzes. Was deliberated again. Following Friday’s review meeting, PTI reported quoting sources.
Covaxin and Covishield are currently awaiting final marketing approval from the Indian Drug Administration (DCGI).
Kovacin will be the first indigenous-developed vaccine to be urgently approved in India.
It was developed by Bharat Biotech in collaboration with the Indian Medical Research Council (ICMR).
Covishield, on the other hand, was developed by AstraZeneca and the University of Oxford and manufactured locally by the Serum Institute.
SII, the world’s largest producer of vaccines, has already stockpiled about 50 million Covishields.
On Friday, the SEC approved Covishield on certain terms.
The panel said that all recipients of the vaccine will be given a fact sheet about the vaccine prior to vaccination.
Manufacturers may also be required to report adverse events every 15 days.
Indian regulators have also received an emergency application for the Covid-19 vaccine created by Pfizer in collaboration with BioNTech in Germany. This is the first shot to secure regulatory approval in the West.
Meanwhile, on Saturday, a national dry run was held to assess the on-site readiness of the vaccination process.
The exercises were held in all state capitals of at least three session sites.
Earlier today, Union Health Minister Harsh Vardhan said the Covid-19 vaccine would be provided free of charge to all Indians.
(There is input from the agency)